Leadership

Management Team

Kleanthis G Xanthopoulos, Ph.D.

CEO

Kleanthis G Xanthopoulos, Ph.D.

Kleanthis G. Xanthopoulos, Ph.D. is a serial entrepreneur whose passion is building healthcare companies focused on innovation. Dr. Xanthopoulos has over two decades of experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor and board member. Dr. Xanthopoulos has founded three companies, has introduced two life science companies to NASDAQ and has financed and brokered numerous creative strategic alliance and partnership deals with large pharmaceutical partners.

Dr. Xanthopoulos is currently the Executive Chairman of IRRAS AB, a commercial stage medical device and drug delivery company, and Managing General Partner at Cerus DMCC, which focuses on investing and building innovative biotechnology companies. Dr. Xanthopoulos served as President and Chief Executive Officer of Regulus Therapeutics Inc. (NASDAQ: RGLS) from the time of its formation in 2007 until June of 2015. Prior to that, he was a Managing Director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) from its inception in 2000 to 2006, and remained a Director until its acquisition by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals, Inc.) from 1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Prior to this, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, he was named the E&Y Entrepreneur of the year in 2006 in San Diego and the San Diego Business Journal’s Most Admired mid-size company CEO in 2013. Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.

In addition to his role at IRRAS AB, Dr. Xanthopoulos is chairman of the board of directors of Apricus Biosciences (NASDAQ: APRI), a director of Zosano Pharma, Inc., (NASDAQ: ZSAN), a director of LDO sp.a. (Milan, Italy), and is the co-founder and a member of the board of directors of privately held Sente Inc. and Aspius Inc.

Christos Panotopoulos, M.D. and Ph.D.

Founder

Chief Scientific Officer

Christos Panotopoulos, M.D. and Ph.D.

Dr. Christos Panotopoulos is a Neurosurgeon and Inventor of medical devices with extensive clinical and research experience in Greece, France, Sweden and India. He is senior consultant Neurosurgeon in Mediterraneo Hospital in Athens, Greece, as well as in BGS Global Hospital and Advanced Neuroscience Institute, Bangalore, India. Dr. Panotopoulos founded IRRAS AB in 2012.

In 2005, he founded and directed Jaymore Enterprises Ltd, a company that developed monitoring and therapeutic medical devices. In 2000, he founded and directed Microdialysis Ltd, a company dedicated to brain tumor research and marketing of the Microdialysis method in Greece, Cyprus and India. Before that, from 1997 – 2000, he contacted preclinical and clinical research in the « Institut Européen des Sciences de Goût et des Comportements Alimentaires » (IESGCA), Dijon, and in INSERM 518-U – Centre Nationale de Recherche Scientifique, Grenoble, France. During the same period he worked in the Neurosurgical Clinic, Hôpital Kremlin-Bicêtre, Université Paris XI, France and the Neurosurgical Clinic, Hôpital Nord, Université Joseph Fourrier, Grenoble, France.

Dr. Panotopoulos graduated and received a Ph. D. degree from the Medical Faculty of Athens University, Greece, holds a title of Speciality in Neurosurgery from Athens Prefecture and a Microsurgery degree from the Faculté de Médecine Paris-Sud, Université Paris XI, France.

K.-Matthias Moehlmann

Executive Vice President Commercial Operations and General Manager Europe

K.-Matthias Moehlmann

Mr. Moehlmann has more than fifteen years of experience as an executive or consultant for leading medical device companies in the neurological, trauma and orthopedic categories. He has achieved broad knowledge, skills and experience in bringing innovative medical technologies to the international healthcare markets. Karl Matthias has managed Commercial Operations, Marketing and R&D for many leading public and private companies, with a proven record of leadership and strategic expertise to deliver bottom line results and achieve business growth.

Mr. Moehlmann was formerly Director of Marketing at Kyphon B.v.B.a, which was acquired by Medtronic and was also VP of Business Development at Bonesupport AB. He has held leadership and consultancy roles at aap Bioimplants, Benvenue Medical, CRA DePuy Spine, X-Spine, Miedke Hydrocephalus Solutions and Mimedx Biologics.

C. Lance Boling

Vice President of Product Development

C. Lance Boling

Mr. Boling has 25 years of executive and consulting experience in medical device development, manufacturing, operations, and strategic management. He was formerly Director of Nano Technology Development at Abbott Laboratories and has driven numerous development efforts from inception through commercialization, including holding key leadership positions in disruptive Silicon Valley start-up ventures such as Nanostim, Nevro Corporation, NeuroPace Inc., and Autonomic Technology.

Mr. Boling has a BA in Business Management from the University of Phoenix as well as Post Graduate studies in Manufacturing Technology at Stanford University. He holds over 40 pioneering patents, granted and pending in the medical device industry, provides guidance to several national and international fledgling start-ups, and is a regular guest lecturer at UC Berkeley School of Engineering.

Fredrik Alpsten

Chief Financial Officer

Deputy Chief Executive Officer

Fredrik Alpsten

Mr. Alpsten brings approximately twenty years of operational, financial, and strategic business experience as an executive in the medical technology field. Most recently, Mr. Alpsten served as Senior Vice President and CFO of Boule Diagnostics AB (Boule), a Swedish publicly-traded diagnostics company. During his six years in this role, Mr. Alpsten was responsible for overseeing multiple global departments including finance, investor relations, administration, IT, legal, human resources, and facilities. During his time at Boule, Mr. Alpsten also served as President and CEO of Clinical Diagnostic Solutions Inc., a US subsidiary of Boule. Prior to his tenure at Boule he was President and CEO of Doxa AB (Doxa), a publicly-traded medical technology company located in Sweden, where he grew the company from a R&D company to a commercial-stage marketing organization with a robust sales presence in the EU and the US. Before serving as President and CEO at Doxa, Mr. Alpsten was VP, CFO of Doxa and prepared the company for an Initial Public Offering on the Nasdaq exchange. Mr. Alpsten also served as Finance Director of N&T Argonaut AB, a publicly-traded company on the Stockholm Stock Exchange, for nine years.In addition to different board assignments for the Boule group, Mr. Alpsten currently serves as Chairman of the Board of Personlig Almanacka Nordic AB and board member and chairman of the audit committee of Oniva Online Group Europe AB. Mr. Alpsten received a Master of Science degree from the Stockholm School of Economics.